Dishman Pharmaceuticals and Chemicals, a Rs.1,100 crore plus Ahmedabad based pharma major, has received minor setback during the third quarter ended December 2012 on account of significant higher interest burden. Its net profit declined by 1.9 per cent to Rs.16.41 crore from Rs.16.72 crore as its interest cost went up sharply to Rs.25.20 crore from Rs.4.88 crore. However, its EBDITA went up 36.8 per cent to Rs.68.37 crore from Rs.49.98 crore. With lower net profit, its EPS worked out to Rs.2.03 as against Rs.2.07 in the last period.
The consolidated net sales increased by 19.7 per cent to Rs.317.57 crore from Rs.265.38 crore in the corresponding period of last year. The sales from CRAMS increased by 23.8 per cent to Rs.209.07 crore from Rs.168.83 crore and that from other increased by 12.4 per cent to Rs.108.50 crore from Rs.96.54 crore.
For the nine months ended December 2012, Dishman's net sales increased by 19.5 per cent to Rs.922 crore from Rs.771 crore. Its net profit went up sharply by 220 per cent to Rs.81.72 crore from Rs.25.51 crore. Similarly, its EBDITA moved up by 52.6 per cent to Rs.221.93 crore from Rs.145.42 crore.
On standalone basis, its net sales improved marginally to Rs.103.30 crore from Rs.100.13 crore during the quarter under review. Its standalone net profit declined sharply by 61.6 per cent to Rs.5.75 crore from Rs.14.97 crore. Standalone EDBITA worked out to Rs.35.90 crore as compared to Rs.32.14 crore.